2022
Missed Opportunities for HIV and Hepatitis C Screening Among Emergency Department Patients With Untreated Opioid Use Disorder
Lyons MS, Chawarski MC, Rothman R, Whiteside L, Cowan E, Richardson LD, Hawk K, Tsui JI, Schwartz RP, O’Connor P, D’Onofrio G, Fiellin DA, Edelman EJ. Missed Opportunities for HIV and Hepatitis C Screening Among Emergency Department Patients With Untreated Opioid Use Disorder. Journal Of Addiction Medicine 2022, 17: 210-214. PMID: 36170184, PMCID: PMC10023471, DOI: 10.1097/adm.0000000000001074.Peer-Reviewed Original ResearchMeSH KeywordsAdultEmergency Service, HospitalHepacivirusHepatitis CHIV InfectionsHumansOpioid-Related DisordersProspective StudiesConceptsUntreated opioid use disorderOpioid use disorderRecent injection drug useEmergency department HIVInjection drug useHCV screeningED patientsUse disordersEnrollment periodDrug useHepatitis C screeningStructured screening programmeUnknown HCV statusUnknown HIV statusHigh-risk cohortMedical care providersHCV statusC screeningHepatitis CED visitsAcademic EDHIV statusEmergency departmentCohort 2Cohort 1
2015
Teaching Psychosocial Interventions for Opioid Use Disorder in Low and Middle Income Countries: Malaysia and China
Marienfeld C, Chawarski M. Teaching Psychosocial Interventions for Opioid Use Disorder in Low and Middle Income Countries: Malaysia and China. Academic Psychiatry 2015, 40: 507-513. PMID: 26626791, DOI: 10.1007/s40596-015-0438-2.Peer-Reviewed Original ResearchEmergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial
D’Onofrio G, O’Connor P, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. JAMA 2015, 313: 1636-1644. PMID: 25919527, PMCID: PMC4527523, DOI: 10.1001/jama.2015.3474.Peer-Reviewed Original ResearchConceptsBrief intervention groupOpioid-dependent patientsIllicit opioid useAddiction treatment servicesPercent of patientsBuprenorphine groupEmergency departmentIntervention groupReferral groupOpioid useTreatment servicesBrief interventionOpioid dependenceClinical trialsHIV riskUrban teaching hospital emergency departmentBuprenorphine/naloxone treatmentHuman immunodeficiency virus (HIV) riskTeaching hospital emergency departmentAddiction treatmentBuprenorphine treatment groupUrine samplesBuprenorphine/naloxoneRandomized clinical trialsCommunity-based treatment servicesExpanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN. Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 554-561. PMID: 25564105, PMCID: PMC4382671, DOI: 10.1097/qai.0000000000000510.Peer-Reviewed Original ResearchConceptsInjection-related risk behaviorsBUP/NXRisk behaviorsOpioid useNegative urinalysisTreatment strategiesInjection opioid useOpioid-dependent PWIDThrice-weekly dosingPrimary end pointBuprenorphine/naloxoneOpioid use disorderOpioid-dependent peopleEvidence-based treatmentsBehavioral drugBuprenorphine-naloxoneDose taperingOpioid injectionWeek 78HIV infectionActive treatmentHIV incidenceWeek 26Treatment optionsTreatment completion
2012
Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia
Chawarski MC, Vicknasingam B, Mazlan M, Schottenfeld RS. Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia. Drug And Alcohol Dependence 2012, 124: 177-180. PMID: 22266088, PMCID: PMC4641448, DOI: 10.1016/j.drugalcdep.2011.12.024.Peer-Reviewed Original ResearchConceptsOpiate injectorsHIV infectionHIV statusATS useLifetime historyAmphetamine-type stimulantsHIV-negative participantsHIV transmission riskHIV-positive participantsDrug use historyPublic health prevention measuresHigh-risk behaviorsHealth prevention measuresTreatment IDUsVs. 75HIV transmissionRisk factorsPositive participantsHIV riskHigh riskRisk behaviorsDrug abuse problemsTransmission riskDrug abuseIDUs
2010
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial
Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial. Drug And Alcohol Dependence 2010, 115: 237-239. PMID: 21159452, PMCID: PMC3076517, DOI: 10.1016/j.drugalcdep.2010.09.024.Peer-Reviewed Original ResearchConceptsHIV risk reduction counselingMethadone maintenance treatmentRisk reduction counselingIllicit opiate useHIV risk behaviorsBehavioral drugReduction counselingClinical trialsOpiate useMMT servicesRisk behaviorsPrimary outcome measurePilot clinical trialTime of enrollmentSignificant baseline differencesHeroin-dependent individualsNegative test resultsMMT clinicsDaily medicationMaintenance treatmentMMT programBaseline differencesOutcome measuresMMT groupTreatment retention
2008
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. The Lancet 2008, 371: 2192-2200. PMID: 18586174, PMCID: PMC4041792, DOI: 10.1016/s0140-6736(08)60954-x.Peer-Reviewed Original ResearchConceptsFirst heroin useHIV risk behaviorsHeroin dependenceHeroin useHeroin relapseMaintenance treatmentHeroin abstinenceDrug counsellingComputer-generated randomisation sequenceRisk behaviorsEffective public health approachConsecutive daysInterim safety analysisOutpatient research clinicPlacebo-controlled trialEfficacy of naltrexoneHeroin-dependent patientsMonths of enrollmentPrevention of relapseWorldwide health priorityPublic health approachRandomisation sequencePrimary outcomeHIV transmissionHIV risk
2007
Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial
Chawarski MC, Mazlan M, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial. Drug And Alcohol Dependence 2007, 94: 281-284. PMID: 18164145, DOI: 10.1016/j.drugalcdep.2007.11.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentOpioid-negative urine testsHIV risk reduction counselingRisk reduction counselingHIV risk behaviorsBehavioral drugReduction counselingUrine testsClinical trialsDrug counselingRisk behaviorsSelf-reported HIV risk behaviorsTake-home dosesUrine toxicology testsHeroin-dependent individualsIndividual drug counselingSelf-reported drug useMaintenance treatmentMedication adherenceLimited counselingBuprenorphineDrug useConsecutive abstinenceToxicology testsOverall proportionBuprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal Of Substance Use And Addiction Treatment 2007, 35: 87-92. PMID: 17933486, PMCID: PMC2587397, DOI: 10.1016/j.jsat.2007.08.004.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentNaloxone treatmentHIV risk behaviorsHIV riskRisk behaviorsHuman immunodeficiency virus (HIV) risk behaviorsDrug-related HIV riskHuman immunodeficiency virus (HIV) riskSex-related HIV risk behaviorsBuprenorphine/naloxoneIntravenous drug useOpioid-dependent personsPrimary care clinicsInconsistent condom useBuprenorphine/Care clinicsMethadone treatmentPrimary careDrug useSteady partnerCondom useBaselineWeeksTreatmentPatients
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependenceASIA PACIFIC COLUMN: New challenges and opportunities in managing substance abuse in Malaysia
MAZLAN M, SCHOTTENFELD RS, CHAWARSKI MC. ASIA PACIFIC COLUMN: New challenges and opportunities in managing substance abuse in Malaysia. Drug And Alcohol Review 2006, 25: 473-478. PMID: 16939945, DOI: 10.1080/09595230600883354.Peer-Reviewed Original ResearchConceptsStimulant abuseDrug useRelated disordersAgonist maintenance treatmentInjection drug useHealth careHigh HIV prevalenceHeroin-dependent individualsOpiate-dependent patientsSevere drug problemsInfectious disease ratesAgonist medicationsHIV casesMaintenance treatmentHIV prevalenceCountry's health careHeroin abusersMedical treatmentHeroin usersTreatment approachesDrug abusersDrug usersAdult populationDisease ratesSubstance abuseHeroin dependence and HIV infection in Malaysia
Chawarski MC, Mazlan M, Schottenfeld RS. Heroin dependence and HIV infection in Malaysia. Drug And Alcohol Dependence 2006, 82: s39-s42. PMID: 16769444, DOI: 10.1016/s0376-8716(06)80007-4.Peer-Reviewed Original ResearchConceptsInjection drug useCurrent injection drug useLifetime injection drug useHIV infectionNeedle sharingHepatitis CHeroin dependenceHigh prevalenceDrug useMajor risk factorChest X-rayHeroin-dependent individualsHIV risk behaviorsHeroin-dependent subjectsConsistent condom useAddiction Severity IndexDrug abuse treatmentRadiological evidenceHepatitis BMean ageRisk factorsClinical trialsMalay ethnicityBaseline assessmentHIV
1998
Assessment of HIV Risk
Chawarski M, Pakes J, Schottenfeld R. Assessment of HIV Risk. Journal Of Addictive Diseases 1998, 17: 49-59. PMID: 9848031, DOI: 10.1300/j069v17n04_05.Peer-Reviewed Original Research